| Literature DB >> 24679597 |
Sofia Lejon Crottet1, Christine Henny1, Stefan Meyer2, Franziska Still1, Martin Stolz1, Jochen Gottschalk2, Kathrin Neuenschwander2, Behrouz Mansouri Taleghani3, Peter Gowland1, Beat M Frey2, Stefano Fontana1, Hein Hustinx1, Christoph Niederhauser4, Christoph Gassner5.
Abstract
Starting in 2013, blood donors must be tested at least using: (1) one monoclonal anti-D and one anti-CDE (alternatively full RhCcEe phenotyping), and (2) all RhD negative donors must be tested for RHD exons 5 and 10 plus one further exonic, or intronic RHD specificity, according to the guidelines of the Blood Transfusion Service of the Swiss Red Cross (BTS SRC). In 2012 an adequate stock of RHD screened donors was built. Of all 25,370 RhD negative Swiss donors tested in 2012, 20,015 tested at BTS Berne and 5355 at BTS Zürich, showed 120 (0.47%) RHD positivity. Thirty-seven (0.15%) had to be redefined as RhD positive. Routine molecular RHD screening is reliable, rapid and cost-effective and provides safer RBC units in Switzerland.Entities:
Keywords: Molecular RHD screening; National guidelines; Rhesus D
Mesh:
Substances:
Year: 2014 PMID: 24679597 DOI: 10.1016/j.transci.2014.02.011
Source DB: PubMed Journal: Transfus Apher Sci ISSN: 1473-0502 Impact factor: 1.764